Dr Denis Ravel

Denis Ravel has over 35 years of experience in pharmaceutical R&D activities at both a large pharmaceutical and young biotech companies. He is the founder of Initial R&D Consulting, a consulting firm supporting young biotech companies in the preclinical (pharmacology, toxicology, pharmacokinetics) and early clinical development of therapeutic molecules.

Denis Ravel is an engineer in Biology with a Ph.D. in Biochemistry from the Pierre & Marie Curie University (Paris). He began his career at Servier, where he was successively responsible for pharmacology, preclinical and early clinical development (Phase I and II) of new molecules in the field of metabolic diseases. In 2001, He joined Genset/Merck-Serono, where he served, first as Director of Pharmaceutical Development at the Paris headquarters, and eventually as Director of the Research Center in San Diego, California. From 2003 to 2007 he was Chief R&D Officer at Diatos, a company focused on the development of new anticancer tumor targeting technologies. He brought two compounds from research to clinical stages.